Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J. 1991;121:1274–82.

Article  CAS  PubMed  Google Scholar 

Inoue T, Node K. Vascular failure: a new clinical entity for vascular disease. J Hypertens. 2006;24:2121–30.

Article  CAS  PubMed  Google Scholar 

Liu C, Liu T, Zhang Q, Song M, Zhang Q, Shi J, et al. Temporal relationship between inflammation and metabolic disorders and their impact on cancer risk. J Glob Health. 2024;14:04041.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98.

Article  PubMed  Google Scholar 

Seravalle G, Grassi G. Obesity and hypertension. Pharm Res. 2017;122:1–7.

Article  CAS  Google Scholar 

Nakamura K, Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, et al. The proportion of individuals with obesity-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA80, 90. Eur J Epidemiol. 2007;22:691–8.

Article  PubMed  Google Scholar 

Zhang L, Dai S, Chen Y, Jin T, Li W, Wang W, et al. Scoping review of obesity interventions: Research frontiers and publication status. iScience. 2024;27:109240.

Article  PubMed  PubMed Central  Google Scholar 

Kawasoe S, Kubozono T, Salim AA, Ojima S, Yamaguchi S, Ikeda Y, et al. Association between anthropometric indices and 5-year hypertension incidence in the general Japanese population. Hypertens Res. 2024;47:867–76.

Ishida A, Taira H, Shinzato T, Ohya Y. Association between visceral fat mass and arterial stiffness among community-based screening participants. Hypertens Res. 2023;46:2488–96.

Article  CAS  PubMed  Google Scholar 

Wu YJ, Jiang CQ, Zhu T, Jin YL, Zhu F, Zhou BJ, et al. Obesity indicators as mediators of the association between age at menopause and blood pressure values. Hypertens Res. 2023;46:1100–9.

Article  CAS  PubMed  Google Scholar 

Fukumine Y, Nakamura K. Obesity and hypertension from a public health perspective in a small remote island of Okinawa, Japan. Hypertens Res. 2023;46:1850–9.

Article  PubMed  Google Scholar 

Lee DC, Brellenthin AG, Lanningham-Foster LM, Kohut ML, Li Y. Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial. Eur Heart J. 2024;45:1127–42.

Article  PubMed  PubMed Central  Google Scholar 

Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:1223–32.

Article  PubMed  Google Scholar 

Sawami K, Tanaka A, Node K. Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2022;21:176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10:193–206.

Article  CAS  PubMed  Google Scholar 

Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–9.

Article  PubMed  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

Article  CAS  PubMed  Google Scholar 

Tan B, Pan XH, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677–85.

Article  CAS  PubMed  Google Scholar 

Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.

Article  CAS  PubMed  Google Scholar 

Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.

Article  CAS  PubMed  Google Scholar 

Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84.

Article  CAS  PubMed  Google Scholar 

Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, Vizzardi E, Tomasoni D, et al. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. 2024;11:649–61.

Article  PubMed  Google Scholar 

Tatsumi Y, Ohkubo T. Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese. Hypertens Res. 2017;40:795–806.

Article  PubMed  Google Scholar 

Yamada MH, Fujihara K, Kodama S, Sato T, Osawa T, Yaguchi Y, et al. Associations of systolic blood pressure and diastolic blood pressure with the incidence of coronary artery disease or cerebrovascular disease according to glucose status. Diabetes Care. 2021;44:2124–31.

Article  CAS  PubMed  Google Scholar 

Tanaka A, Node K. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials. Cardiovasc Diabetol. 2019;18:19.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki D, Hoshide S, Kario K. Impact of diabetic status and contribution of office and home blood pressure across diabetic status for cardiovascular disease: the J-HOP study. Hypertens Res. 2023;46:1684–93.

Article  PubMed  Google Scholar 

Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601–10.

Article  PubMed  Google Scholar 

Gao Q, Lin Y, Xu R, Luo F, Chen R, Li P, et al. Positive association of triglyceride-glucose index with new-onset hypertension among adults: a national cohort study in China. Cardiovasc Diabetol. 2023;22:58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JH, Heo SJ, Kwon YJ. Sex-specific comparison between triglyceride glucose index and modified triglyceride glucose indices to predict new-onset hypertension in middle-aged and older adults. J Am Heart Assoc. 2023;12:e030022.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xin F, He S, Zhou Y, Jia X, Zhao Y, Zhao H. The triglyceride glucose index trajectory is associated with hypertension: a retrospective longitudinal cohort study. Cardiovasc Diabetol. 2023;22:347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang S, Wang C, Zhang J, Liu Z, Bai Y, Chen Z, et al. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. 2023;22:170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Tan Z, Huang Y, Zhao H, Liu M, Yu P, et al. Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21:124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4:e23–e33.

Article  PubMed  Google Scholar 

Miao H, Zhou Z, Yang S, Zhang Y. The association of triglyceride-glucose index and related parameters with hypertension and cardiovascular risk: a cross-sectional study. Hypertens Res. 2024;47:877–86.

Sakoda T, Akasaki Y, Sasaki Y, Kawasoe S, Kubozono T, Ikeda Y, et al. Triglyceride-glucose index predicts future chronic kidney disease development in all populations, including normotensive and isolated diastolic hypertension. Hypertens Res. 2024;47:149–56.

Article  CAS  PubMed  Google Scholar 

Sawami K, Tanaka A, Node K. Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone? Hypertens Res. 2023;46:1892–9.

Article  CAS  PubMed  Google Scholar 

Tanaka A, Node K. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents. Hypertens Res. 2021;44:897–905.

Article  PubMed  Google Scholar 

Saito Y, Tanaka A, Imai T, Nakamura I, Kanda J, Matsuhisa M, et al. Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial. Hypertens Res. 2024;47:168–76.

Article  CAS